Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies$4,995
- March - 2016
- In Pharmaceuticals
- By GBI Research 644 Views
Alzheimer Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive ………..
Total Pages: 151